These different median allele frequency rates of pathogenic KRAS mutations between short- and long-term PDAC survivors might be explained by the role of KRAS mutations in inducing tumor progression, with tumors showing higher allele frequency rates for pathogenic KRAS mutations, i.e., tumors harboring a higher proportion of KRAS-mutated subclones, showing a faster tumor progression, hence its link to early disease recurrence in our study. The gene discussed is KRAS; the disease is neoplasm.